Go to Patients & Caregivers Site
Customer Contact Center:
1-888-PLMZYME (756-9963)

Indication Statement:

Daily administration of Pulmozyme (dornase alfa) in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. Safety and efficacy of daily administration have not been demonstrated in patients for longer than twelve months.

Important Safety Information

  • Pulmozyme should not be used in patients with known hypersensitivity to dornase alfa, or any ingredients of the product.
  • Pulmozyme should be used in conjunction with standard therapies for CF.
  • Most common reported adverse events associated with the use of Pulmozyme include: voice alteration, pharyngitis, laryngitis, rash, chest pain, and conjunctivitis.

Resources

Resources

Information, research and support for you and your patients

Genentech® is committed to providing you and your patients with the information and support you need in the fight against CF.

Resources for you. Find information about our Research Contracts and Reagents Program, the Epidemiologic Study of Cystic Fibrosis II, publications and abstracts, as well as third-party links to information about cystic fibrosis. See resources for healthcare providers ›

Resources for your patients. Learn about CF Living, an online community where CF patients and caregivers can find advice and share stories. Additionally, you'll find an FAQ with commonly asked patient questions about CF and Pulmozyme treatment. See resources to share with patients ›

Next:
Resources for You ›